Podcasts about TB

Discover how to master GLP-1 peptides for fat loss and muscle gain simultaneously in this power-packed episode of Mark Bell's Power Project!

In this episode, Dr. Jockers and Dr. Rob Bello dive into the science behind BPC-157 and why it's different from conventional anti-inflammatories like NSAIDs. You'll hear how this peptide works with your body—not against it—to speed healing and reduce chronic inflammation without halting the recovery process.   You'll also discover the power of stacking BPC-157 with TB-4 Frag, a synergistic combo known as the “Wolverine Stack.” Learn how this potent pair supports tissue repair, collagen production, angiogenesis, and even hormone receptor sensitivity for faster recovery and better performance.   Curious about dosing, delivery methods, or long-term safety? Dr. Bello shares insider insights on oral bioavailability, clinical outcomes, and what makes their formulations uniquely effective—especially for athletes, autoimmune patients, and anyone dealing with chronic pain.   In This Episode: 00:00 Introduction to Inflammation and BPC 03:23 Dr. Jocker's Personal Experience with BPC 157 04:33 Interview with Dr. Rob Bello: Peptides and BPC 157 04:55 The Origin and Benefits of BPC 157 09:48 BPC 157: Mechanisms and Healing Properties 20:14 BPC 157: Dosage and Administration 28:00 Understanding Lip Polysaccharides and Inflammation 28:23 Why Most New Year's Resolutions Fail 30:24 The Role of Endotoxin Labs in Autoimmune Treatment 31:30 Exploring TB 500 and Its Benefits 37:21 The Wolverine Stack: Enhancing Healing and Recovery 46:41 Ensuring Quality and Efficacy in Supplements 51:29 Conclusion and Final Thoughts     Support your heart, brain, and immune system with Paleo Valley's Wild Caught Fish Roe, a whole food source rich in Omega-3s like EPA and DHA. It's more bioavailable and stable than traditional fish oil, offering benefits for cardiovascular health, mood, and brain function. Go to paleovalley.com/jockers for 15% off your order!   Looking to boost your digestion, immunity, and energy? Just Thrive Probiotic is the answer! Unlike most probiotics that get destroyed by stomach acid, Just Thrive is clinically proven to reach your gut 100% alive. This means better digestion, improved immunity, enhanced energy, and easier weight management. Plus, with their industry-leading 100% money-back guarantee, you've got nothing to lose. Start feeling your best today, go to justthrivehealth.com and use code JOCKERS to save 20%.   Turn on your body's ability to heal with Vibrant Blue Oils, particularly their parasympathetic blend. These natural essential oils activate your nervous system, reduce inflammation, enhance digestion, detoxification, and improve brain function. Visit vibrantblueoils.com/jockers to grab a $15 full-size bottle of their Parasympathetic Blend today!"       "BPC-157 doesn't block inflammation. It empowers the healing process by regulating inflammation where it's needed." ~ Dr. Jockers     Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean  TuneIn Radio     Resources: Get 15% off Paleovalley Fish Roe: paleovalley.com/jockers – Use code JOCKERS Save 20% on Just Thrive: justthrivehealth.com – Use code JOCKERS Visit vibrantblueoils.com/jockers and save $15 on a full-size bottle today!       Connect with Dr. Rob Bello: Website: https://bellofamilychiropractic.com/   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https:/www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/

Send us a textWhat a ride it's been! The most corrupt trial in American history is over. Judge Bev openly put her thumb on the scale of justice, that is simply a fact. Will she be reprimanded? counseled? questioned? No, simply no. Will there be a blue ribbon commission of Massachusetts State Police? No they've stated they'll remedy the planting of evidence, through a citizens police academy? Did you just chuckle? This IS happening. Massachusetts corruption continues unabated. That is the toughest part of the trial, NOTHING will change. Please share-yea right now!TB interviews Allan Jackson-https://bit.ly/405jZSZBrother Counsel interviews KR's civil attorneyhttps://bit.ly/4eC1kUNX-bcpbeantown Email-barry@bostonconfidential.net

Tựa Đề: Chúa Chỉ Như Ngài Tự Bày Tỏ; Kinh Thánh: Xuất Ê-díp-tô Ký 32:1-10; Công-vụ các Sứ-đồ 2:1-21; Tác Giả: Mục Sư Trịnh Văn Khánh; Loạt Bài: Hội Thánh Tin Lành Trưởng Nhiệm Ân Điển

Send us a textThe cutting edge of infectious disease control isn't just about vaccines or treatments—it's increasingly about data. Dr. Stephen Molldrem, Assistant Professor at the Institute for Bioethics and Health Humanities, takes us deep into the world of pathogen genomics and the remarkable ethical questions that emerge when we sequence disease-causing microorganisms.What happens when genetic analysis can potentially reveal who infected whom with HIV? Why do some communities welcome these technologies while others resist them? From the controversies surrounding HIV surveillance in America to the enthusiastic adoption of TB genomics in Botswana, Dr. Molldrem reveals how the same scientific tools can take on dramatically different meanings depending on context, trust, and community involvement.The COVID-19 pandemic accelerated the global adoption of pathogen sequencing, bringing terms like "variants" and "mutations" into everyday conversation. But this technological revolution has also revealed deep inequities—when South African scientists identified the Omicron variant and transparently shared this information, their reward was travel bans rather than support. This pattern reveals how scientific advancement doesn't happen in a vacuum but within complex social and political realities.At the heart of Dr. Molldrem's work is a fundamental reminder: behind every genetic sequence is a person, a community, and a set of lived experiences. As one HIV advocacy slogan puts it, "We are people, not clusters." The challenge for public health isn't just implementing new technologies but doing so in ways that respect human dignity and build rather than undermine trust.Whether you're fascinated by the science of disease tracking, concerned about health privacy, or interested in how new technologies reshape our understanding of outbreaks, this episode offers a thought-provoking journey through the socio-technical landscape of modern infectious disease control. Join us as we explore what happens when cutting-edge science meets complex human realities.Thanks for listening to the Infectious Science Podcast. Be sure to visit infectiousscience.org to join the conversation, access the show notes, and don't forget to sign up for our newsletter to receive our free materials. We hope you enjoyed this new episode of Infectious Science, and if you did, please leave us a review on Apple Podcasts and Spotify. Please share this episode with others who may be interested in this topic! Also, please don't hesitate to ask questions or tell us which topics you want us to cover in future episodes. To get in touch, drop us a line in the comment section or send us a message on social media. Instagram @InfectscipodFacebook Infectious Science PodcastSee you next time for a new episode!

Looking for the best MLB picks, predictions, and betting tips for Thursday, July 3, 2025? Tune in to Total Bases with expert handicappers Adam Trigger, Bryan Leonard and Tokyo Brandon as they break down today's MLB matchups with sharp insights and actionable advice.0:00:00 Introduction0:02:11 TB's tirade0:05:45 New York Mets vs. Milwaukee Brewers0:14:40 Houston Astros vs. Colorado Rockies0:23:48 Minnesota Twins vs. Miami Marlins0:32:15 Los Angeles Angels vs. Atlanta Braves0:44:14 Detroit Tigers vs. Washington Nationals0:55:34 New York Yankees vs. Toronto Blue Jays1:01:29 Parlay of the Day

Granulomatosis with Polyangiitis (GPA) – Recognition and Management in the ED Hosts: Phoebe Draper, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/GPA.mp3 Download Leave a Comment Tags: Rheumatology Show Notes Background A vasculitis affecting small blood vessels causing inflammation and necrosis Affects upper respiratory tract (sinusitis, otitis media, saddle nose deformity), lungs (nodules, alveolar hemorrhage), and kidneys (rapidly progressive glomerulonephritis) Can lead to multi-organ failure, pulmonary hemorrhage, renal failure Red Flag Symptoms: Chronic sinus symptoms Hemoptysis (especially bright red blood) New pulmonary complaints Renal dysfunction Constitutional symptoms (fatigue, weight loss, fever) Workup in the ED: CBC, CMP for anemia and AKI Urinalysis with microscopy (hematuria, RBC casts) Chest imaging (CXR or CT for nodules, cavitary lesions) ANCA testing (not immediately available but important diagnostically) Management: Stable patients: Outpatient workup, urgent rheumatology consult, prednisone 1 mg/kg/day Unstable patients: High-dose IV steroids (methylprednisolone 1 g daily x3 days), consider plasma exchange, cyclophosphamide or rituximab initiation, ICU admission Conditions that Mimic GPA: Goodpasture syndrome (anti-GBM antibodies) TB, fungal infections Lung malignancy Other vasculitides (EGPA, MPA, lupus)

7:09 News 24:22 Comic reviews25:41 Absolute Wonder Woman #927:51 Witcher B&TB #228:39 Ultramega #930:48 Uncanny X-Men #1631:43 Pale Knight #233:25 The Thing #235:06 Sonic the Hedgehog #7936:30 DC x Sonic #439:26 Green Lantern #2440:45 New History of the DCU #142:57 Minor Arcana #845:14 Incredible Hulk #2647:44 JLU #851:55 Superman #2754:34 What we are excited for55:53 Fantastic Four

“To navigate proof, we must reach into a thicket of errors and biases. We must confront monsters and embrace uncertainty, balancing — and rebalancing —our beliefs. We must seek out every useful fragment of data, gather every relevant tool, searching wider and climbing further. Finding the good foundations among the bad. Dodging dogma and falsehoods. Questioning. Measuring. Triangulating. Convincing. Then perhaps, just perhaps, we'll reach the truth in time.”—Adam KucharskiMy conversation with Professor Kucharski on what constitutes certainty and proof in science (and other domains), with emphasis on many of the learnings from Covid. Given the politicization of science and A.I.'s deepfakes and power for blurring of truth, it's hard to think of a topic more important right now.Audio file (Ground Truths can also be downloaded on Apple Podcasts and Spotify)Eric Topol (00:06):Hello, it's Eric Topol from Ground Truths and I am really delighted to welcome Adam Kucharski, who is the author of a new book, Proof: The Art and Science of Certainty. He's a distinguished mathematician, by the way, the first mathematician we've had on Ground Truths and a person who I had the real privilege of getting to know a bit through the Covid pandemic. So welcome, Adam.Adam Kucharski (00:28):Thanks for having me.Eric Topol (00:30):Yeah, I mean, I think just to let everybody know, you're a Professor at London School of Hygiene and Tropical Medicine and also noteworthy you won the Adams Prize, which is one of the most impressive recognitions in the field of mathematics. This is the book, it's a winner, Proof and there's so much to talk about. So Adam, maybe what I'd start off is the quote in the book that captivates in the beginning, “life is full of situations that can reveal remarkably large gaps in our understanding of what is true and why it's true. This is a book about those gaps.” So what was the motivation when you undertook this very big endeavor?Adam Kucharski (01:17):I think a lot of it comes to the work I do at my day job where we have to deal with a lot of evidence under pressure, particularly if you work in outbreaks or emerging health concerns. And often it really pushes the limits, our methodology and how we converge on what's true subject to potential revision in the future. I think particularly having a background in math's, I think you kind of grow up with this idea that you can get to these concrete, almost immovable truths and then even just looking through the history, realizing that often isn't the case, that there's these kind of very human dynamics that play out around them. And it's something I think that everyone in science can reflect on that sometimes what convinces us doesn't convince other people, and particularly when you have that kind of urgency of time pressure, working out how to navigate that.Eric Topol (02:05):Yeah. Well, I mean I think these times of course have really gotten us to appreciate, particularly during Covid, the importance of understanding uncertainty. And I think one of the ways that we can dispel what people assume they know is the famous Monty Hall, which you get into a bit in the book. So I think everybody here is familiar with that show, Let's Make a Deal and maybe you can just take us through what happens with one of the doors are unveiled and how that changes the mathematics.Adam Kucharski (02:50):Yeah, sure. So I think it is a problem that's been around for a while and it's based on this game show. So you've got three doors that are closed. Behind two of the doors there is a goat and behind one of the doors is a luxury car. So obviously, you want to win the car. The host asks you to pick a door, so you point to one, maybe door number two, then the host who knows what's behind the doors opens another door to reveal a goat and then ask you, do you want to change your mind? Do you want to switch doors? And a lot of the, I think intuition people have, and certainly when I first came across this problem many years ago is well, you've got two doors left, right? You've picked one, there's another one, it's 50-50. And even some quite well-respected mathematicians.Adam Kucharski (03:27):People like Paul Erdős who was really published more papers than almost anyone else, that was their initial gut reaction. But if you work through all of the combinations, if you pick this door and then the host does this, and you switch or not switch and work through all of those options. You actually double your chances if you switch versus sticking with the door. So something that's counterintuitive, but I think one of the things that really struck me and even over the years trying to explain it is convincing myself of the answer, which was when I first came across it as a teenager, I did quite quickly is very different to convincing someone else. And even actually Paul Erdős, one of his colleagues showed him what I call proof by exhaustion. So go through every combination and that didn't really convince him. So then he started to simulate and said, well, let's do a computer simulation of the game a hundred thousand times. And again, switching was this optimal strategy, but Erdős wasn't really convinced because I accept that this is the case, but I'm not really satisfied with it. And I think that encapsulates for a lot of people, their experience of proof and evidence. It's a fact and you have to take it as given, but there's actually quite a big bridge often to really understanding why it's true and feeling convinced by it.Eric Topol (04:41):Yeah, I think it's a fabulous example because I think everyone would naturally assume it's 50-50 and it isn't. And I think that gets us to the topic at hand. What I love, there's many things I love about this book. One is that you don't just get into science and medicine, but you cut across all the domains, law, mathematics, AI. So it's a very comprehensive sweep of everything about proof and truth, and it couldn't come at a better time as we'll get into. Maybe just starting off with math, the term I love mathematical monsters. Can you tell us a little bit more about that?Adam Kucharski (05:25):Yeah, this was a fascinating situation that emerged in the late 19th century where a lot of math's, certainly in Europe had been derived from geometry because a lot of the ancient Greek influence on how we shaped things and then Newton and his work on rates of change and calculus, it was really the natural world that provided a lot of inspiration, these kind of tangible objects, tangible movements. And as mathematicians started to build out the theory around rates of change and how we tackle these kinds of situations, they sometimes took that intuition a bit too seriously. And there was some theorems that they said were intuitively obvious, some of these French mathematicians. And so, one for example is this idea of you how things change smoothly over time and how you do those calculations. But what happened was some mathematicians came along and showed that when you have things that can be infinitely small, that intuition didn't necessarily hold in the same way.Adam Kucharski (06:26):And they came up with these examples that broke a lot of these theorems and a lot of the establishments at the time called these things monsters. They called them these aberrations against common sense and this idea that if Newton had known about them, he never would've done all of his discovery because they're just nuisances and we just need to get rid of them. And there's this real tension at the core of mathematics in the late 1800s where some people just wanted to disregard this and say, look, it works for most of the time, that's good enough. And then others really weren't happy with this quite vague logic. They wanted to put it on much sturdier ground. And what was remarkable actually is if you trace this then into the 20th century, a lot of these monsters and these particularly in some cases functions which could almost move constantly, this constant motion rather than our intuitive concept of movement as something that's smooth, if you drop an apple, it accelerates at a very smooth rate, would become foundational in our understanding of things like probability, Einstein's work on atomic theory. A lot of these concepts where geometry breaks down would be really important in relativity. So actually, these things that we thought were monsters actually were all around us all the time, and science couldn't advance without them. So I think it's just this remarkable example of this tension within a field that supposedly concrete and the things that were going to be shunned actually turn out to be quite important.Eric Topol (07:53):It's great how you convey how nature isn't so neat and tidy and things like Brownian motion, understanding that, I mean, just so many things that I think fit into that general category. In the legal, we won't get into too much because that's not so much the audience of Ground Truths, but the classic things about innocent and until proven guilty and proof beyond reasonable doubt, I mean these are obviously really important parts of that overall sense of proof and truth. We're going to get into one thing I'm fascinated about related to that subsequently and then in science. So before we get into the different types of proof, obviously the pandemic is still fresh in our minds and we're an endemic with Covid now, and there are so many things we got wrong along the way of uncertainty and didn't convey that science isn't always evolving search for what is the truth. There's plenty no shortage of uncertainty at any moment. So can you recap some of the, you did so much work during the pandemic and obviously some of it's in the book. What were some of the major things that you took out of proof and truth from the pandemic?Adam Kucharski (09:14):I think it was almost this story of two hearts because on the one hand, science was the thing that got us where we are today. The reason that so much normality could resume and so much risk was reduced was development of vaccines and the understanding of treatments and the understanding of variants as they came to their characteristics. So it was kind of this amazing opportunity to see this happen faster than it ever happened in history. And I think ever in science, it certainly shifted a lot of my thinking about what's possible and even how we should think about these kinds of problems. But also on the other hand, I think where people might have been more familiar with seeing science progress a bit more slowly and reach consensus around some of these health issues, having that emerge very rapidly can present challenges even we found with some of the work we did on Alpha and then the Delta variants, and it was the early quantification of these.Adam Kucharski (10:08):So really the big question is, is this thing more transmissible? Because at the time countries were thinking about control measures, thinking about relaxing things, and you've got this just enormous social economic health decision-making based around essentially is it a lot more spreadable or is it not? And you only had these fragments of evidence. So I think for me, that was really an illustration of the sharp end. And I think what we ended up doing with some of those was rather than arguing over a precise number, something like Delta, instead we kind of looked at, well, what's the range that matters? So in the sense of arguing over whether it's 40% or 50% or 30% more transmissible is perhaps less important than being, it's substantially more transmissible and it's going to start going up. Is it going to go up extremely fast or just very fast?Adam Kucharski (10:59):That's still a very useful conclusion. I think what often created some of the more challenges, I think the things that on reflection people looking back pick up on are where there was probably overstated certainty. We saw that around some of the airborne spread, for example, stated as a fact by in some cases some organizations, I think in some situations as well, governments had a constraint and presented it as scientific. So the UK, for example, would say testing isn't useful. And what was happening at the time was there wasn't enough tests. So it was more a case of they can't test at that volume. But I think blowing between what the science was saying and what the decision-making, and I think also one thing we found in the UK was we made a lot of the epidemiological evidence available. I think that was really, I think something that was important.Adam Kucharski (11:51):I found it a lot easier to communicate if talking to the media to be able to say, look, this is the paper that's out, this is what it means, this is the evidence. I always found it quite uncomfortable having to communicate things where you knew there were reports behind the scenes, but you couldn't actually articulate. But I think what that did is it created this impression that particularly epidemiology was driving the decision-making a lot more than it perhaps was in reality because so much of that was being made public and a lot more of the evidence around education or economics was being done behind the scenes. I think that created this kind of asymmetry in public perception about how that was feeding in. And so, I think there was always that, and it happens, it is really hard as well as a scientist when you've got journalists asking you how to run the country to work out those steps of am I describing the evidence behind what we're seeing? Am I describing the evidence about different interventions or am I proposing to some extent my value system on what we do? And I think all of that in very intense times can be very easy to get blurred together in public communication. I think we saw a few examples of that where things were being the follow the science on policy type angle where actually once you get into what you're prioritizing within a society, quite rightly, you've got other things beyond just the epidemiology driving that.Eric Topol (13:09):Yeah, I mean that term that you just use follow the science is such an important term because it tells us about the dynamic aspect. It isn't just a snapshot, it's constantly being revised. But during the pandemic we had things like the six-foot rule that was never supported by data, but yet still today, if I walk around my hospital and there's still the footprints of the six-foot rule and not paying attention to the fact that this was airborne and took years before some of these things were accepted. The flatten the curve stuff with lockdowns, which I never was supportive of that, but perhaps at the worst point, the idea that hospitals would get overrun was an issue, but it got carried away with school shutdowns for prolonged periods and in some parts of the world, especially very stringent lockdowns. But anyway, we learned a lot.Eric Topol (14:10):But perhaps one of the greatest lessons is that people's expectations about science is that it's absolute and somehow you have this truth that's not there. I mean, it's getting revised. It's kind of on the job training, it's on this case on the pandemic revision. But very interesting. And that gets us to, I think the next topic, which I think is a fundamental part of the book distributed throughout the book, which is the different types of proof in biomedicine and of course across all these domains. And so, you take us through things like randomized trials, p-values, 95 percent confidence intervals, counterfactuals, causation and correlation, peer review, the works, which is great because a lot of people have misconceptions of these things. So for example, randomized trials, which is the temple of the randomized trials, they're not as great as a lot of people think, yes, they can help us establish cause and effect, but they're skewed because of the people who come into the trial. So they may not at all be a representative sample. What are your thoughts about over deference to randomized trials?Adam Kucharski (15:31):Yeah, I think that the story of how we rank evidence in medicines a fascinating one. I mean even just how long it took for people to think about these elements of randomization. Fundamentally, what we're trying to do when we have evidence here in medicine or science is prevent ourselves from confusing randomness for a signal. I mean, that's fundamentally, we don't want to mistake something, we think it's going on and it's not. And the challenge, particularly with any intervention is you only get to see one version of reality. You can't give someone a drug, follow them, rewind history, not give them the drug and then follow them again. So one of the things that essentially randomization allows us to do is, if you have two groups, one that's been randomized, one that hasn't on average, the difference in outcomes between those groups is going to be down to the treatment effect.Adam Kucharski (16:20):So it doesn't necessarily mean in reality that'd be the case, but on average that's the expectation that you'd have. And it's kind of interesting actually that the first modern randomized control trial (RCT) in medicine in 1947, this is for TB and streptomycin. The randomization element actually, it wasn't so much statistical as behavioral, that if you have people coming to hospital, you could to some extent just say, we'll just alternate. We're not going to randomize. We're just going to first patient we'll say is a control, second patient a treatment. But what they found in a lot of previous studies was doctors have bias. Maybe that patient looks a little bit ill or that one maybe is on borderline for eligibility. And often you got these quite striking imbalances when you allowed it for human judgment. So it was really about shielding against those behavioral elements. But I think there's a few situations, it's a really powerful tool for a lot of these questions, but as you mentioned, one is this issue of you have the population you study on and then perhaps in reality how that translates elsewhere.Adam Kucharski (17:17):And we see, I mean things like flu vaccines are a good example, which are very dependent on immunity and evolution and what goes on in different populations. Sometimes you've had a result on a vaccine in one place and then the effectiveness doesn't translate in the same way to somewhere else. I think the other really important thing to bear in mind is, as I said, it's the averaging that you're getting an average effect between two different groups. And I think we see certainly a lot of development around things like personalized medicine where actually you're much more interested in the outcome for the individual. And so, what a trial can give you evidence is on average across a group, this is the effect that I can expect this intervention to have. But we've now seen more of the emergence things like N=1 studies where you can actually over the same individual, particularly for chronic conditions, look at those kind of interventions.Adam Kucharski (18:05):And also there's just these extreme examples where you're ethically not going to run a trial, there's never been a trial of whether it's a good idea to have intensive care units in hospitals or there's a lot of these kind of historical treatments which are just so overwhelmingly effective that we're not going to run trial. So almost this hierarchy over time, you can see it getting shifted because actually you do have these situations where other forms of evidence can get you either closer to what you need or just more feasibly an answer where it's just not ethical or practical to do an RCT.Eric Topol (18:37):And that brings us to the natural experiments I just wrote about recently, the one with shingles, which there's two big natural experiments to suggest that shingles vaccine might reduce the risk of Alzheimer's, an added benefit beyond the shingles that was not anticipated. Your thoughts about natural experiments, because here you're getting a much different type of population assessment, again, not at the individual level, but not necessarily restricted by some potentially skewed enrollment criteria.Adam Kucharski (19:14):I think this is as emerged as a really valuable tool. It's kind of interesting, in the book you're talking to economists like Josh Angrist, that a lot of these ideas emerge in epidemiology, but I think were really then taken up by economists, particularly as they wanted to add more credibility to a lot of these policy questions. And ultimately, it comes down to this issue that for a lot of problems, we can't necessarily intervene and randomize, but there might be a situation that's done it to some extent for us, so the classic example is the Vietnam draft where it was kind of random birthdays with drawn out of lottery. And so, there's been a lot of studies subsequently about the effect of serving in the military on different subsequent lifetime outcomes because broadly those people have been randomized. It was for a different reason. But you've got that element of randomization driving that.Adam Kucharski (20:02):And so again, with some of the recent shingles data and other studies, you might have a situation for example, where there's been an intervention that's somewhat arbitrary in terms of time. It's a cutoff on a birth date, for example. And under certain assumptions you could think, well, actually there's no real reason for the person on this day and this day to be fundamentally different. I mean, perhaps there might be effects of cohorts if it's school years or this sort of thing. But generally, this isn't the same as having people who are very, very different ages and very different characteristics. It's just nature, or in this case, just a policy intervention for a different reason has given you that randomization, which allows you or pseudo randomization, which allows you to then look at something about the effect of an intervention that you wouldn't as reliably if you were just digging into the data of yes, no who's received a vaccine.Eric Topol (20:52):Yeah, no, I think it's really valuable. And now I think increasingly given priority, if you can find these natural experiments and they're not always so abundant to use to extrapolate from, but when they are, they're phenomenal. The causation correlation is so big. The issue there, I mean Judea Pearl's, the Book of Why, and you give so many great examples throughout the book in Proof. I wonder if you could comment that on that a bit more because this is where associations are confused somehow or other with a direct effect. And we unfortunately make these jumps all too frequently. Perhaps it's the most common problem that's occurring in the way we interpret medical research data.Adam Kucharski (21:52):Yeah, I think it's an issue that I think a lot of people get drilled into in their training just because a correlation between things doesn't mean that that thing causes this thing. But it really struck me as I talked to people, researching the book, in practice in research, there's actually a bit more to it in how it's played out. So first of all, if there's a correlation between things, it doesn't tell you much generally that's useful for intervention. If two things are correlated, it doesn't mean that changing that thing's going to have an effect on that thing. There might be something that's influencing both of them. If you have more ice cream sales, it will lead to more heat stroke cases. It doesn't mean that changing ice cream sales is going to have that effect, but it does allow you to make predictions potentially because if you can identify consistent patterns, you can say, okay, if this thing going up, I'm going to make a prediction that this thing's going up.Adam Kucharski (22:37):So one thing I found quite striking, actually talking to research in different fields is how many fields choose to focus on prediction because it kind of avoids having to deal with this cause and effect problem. And even in fields like psychology, it was kind of interesting that there's a lot of focus on predicting things like relationship outcomes, but actually for people, you don't want a prediction about your relationship. You want to know, well, how can I do something about it? You don't just want someone to sell you your relationship's going to go downhill. So there's almost part of the challenge is people just got stuck on prediction because it's an easier field of work, whereas actually some of those problems will involve intervention. I think the other thing that really stood out for me is in epidemiology and a lot of other fields, rightly, people are very cautious to not get that mixed up.Adam Kucharski (23:24):They don't want to mix up correlations or associations with causation, but you've kind of got this weird situation where a lot of papers go out of their way to not use causal language and say it's an association, it's just an association. It's just an association. You can't say anything about causality. And then the end of the paper, they'll say, well, we should think about introducing more of this thing or restricting this thing. So really the whole paper and its purpose is framed around a causal intervention, but it's extremely careful throughout the paper to not frame it as a causal claim. So I think we almost by skirting that too much, we actually avoid the problems that people sometimes care about. And I think a lot of the nice work that's been going on in causal inference is trying to get people to confront this more head on rather than say, okay, you can just stay in this prediction world and that's fine. And then just later maybe make a policy suggestion off the back of it.Eric Topol (24:20):Yeah, I think this is cause and effect is a very alluring concept to support proof as you so nicely go through in the book. But of course, one of the things that we use to help us is the biological mechanism. So here you have, let's say for example, you're trying to get a new drug approved by the Food and Drug Administration (FDA), and the request is, well, we want two trials, randomized trials, independent. We want to have p-values that are significant, and we want to know the biological mechanism ideally with the dose response of the drug. But there are many drugs as you review that have no biological mechanism established. And even when the tobacco problems were mounting, the actual mechanism of how tobacco use caused cancer wasn't known. So how important is the biological mechanism, especially now that we're well into the AI world where explainability is demanded. And so, we don't know the mechanism, but we also don't know the mechanism and lots of things in medicine too, like anesthetics and even things as simple as aspirin, how it works and many others. So how do we deal with this quest for the biological mechanism?Adam Kucharski (25:42):I think that's a really good point. It shows almost a lot of the transition I think we're going through currently. I think particularly for things like smoking cancer where it's very hard to run a trial. You can't make people randomly take up smoking. Having those additional pieces of evidence, whether it's an analogy with a similar carcinogen, whether it's a biological mechanism, can help almost give you more supports for that argument that there's a cause and effect going on. But I think what I found quite striking, and I realized actually that it's something that had kind of bothered me a bit and I'd be interested to hear whether it bothers you, but with the emergence of AI, it's almost a bit of the loss of scientific satisfaction. I think you grow up with learning about how the world works and why this is doing what it's doing.Adam Kucharski (26:26):And I talked for example of some of the people involved with AlphaFold and some of the subsequent work in installing those predictions about structures. And they'd almost made peace with it, which I found interesting because I think they started off being a bit uncomfortable with like, yeah, you've got these remarkable AI models making these predictions, but we don't understand still biologically what's happening here. But I think they're just settled in saying, well, biology is really complex on some of these problems, and if we can have a tool that can give us this extremely valuable information, maybe that's okay. And it was just interesting that they'd really kind of gone through that kind process, which I think a lot of people are still grappling with and that almost that discomfort of using AI and what's going to convince you that that's a useful reliable prediction whether it's something like predicting protein folding or getting in a self-driving car. What's the evidence you need to convince you that's reliable?Eric Topol (27:26):Yeah, no, I'm so glad you brought that up because when Demis Hassabis and John Jumper won the Nobel Prize, the point I made was maybe there should be an asterisk with AI because they don't know how it works. I mean, they had all the rich data from the protein data bank, and they got the transformer model to do it for 200 million protein structure prediction, but they still to this day don't fully understand how the model really was working. So it reinforces what you're just saying. And of course, it cuts across so many types of AI. It's just that we tend to hold different standards in medicine not realizing that there's lots of lack of explainability for routine medical treatments today. Now one of the things that I found fascinating in your book, because there's different levels of proof, different types of proof, but solid logical systems.Eric Topol (28:26):And on page 60 of the book, especially pertinent to the US right now, there is a bit about Kurt Gödel and what he did there was he basically, there was a question about dictatorship in the US could it ever occur? And Gödel says, “oh, yes, I can prove it.” And he's using the constitution itself to prove it, which I found fascinating because of course we're seeing that emerge right now. Can you give us a little bit more about this, because this is fascinating about the Fifth Amendment, and I mean I never thought that the Constitution would allow for a dictatorship to emerge.Adam Kucharski (29:23):And this was a fascinating story, Kurt Gödel who is one of the greatest logical minds of the 20th century and did a lot of work, particularly in the early 20th century around system of rules, particularly things like mathematics and whether they can ever be really fully satisfying. So particularly in mathematics, he showed that there were this problem that is very hard to have a set of rules for something like arithmetic that was both complete and covered every situation, but also had no contradictions. And I think a lot of countries, if you go back, things like Napoleonic code and these attempts to almost write down every possible legal situation that could be imaginable, always just ascended into either they needed amendments or they had contradictions. I think Gödel's work really summed it up, and there's a story, this is in the late forties when he had his citizenship interview and Einstein and Oskar Morgenstern went along as witnesses for him.Adam Kucharski (30:17):And it's always told as kind of a lighthearted story as this logical mind, this academic just saying something silly in front of the judge. And actually, to my own admission, I've in the past given talks and mentioned it in this slightly kind of lighthearted way, but for the book I got talking to a few people who'd taken it more seriously. I realized actually he's this extremely logically focused mind at the time, and maybe there should have been something more to it. And people who have kind of dug more into possibilities was saying, well, what could he have spotted that bothered him? And a lot of his work that he did about consistency in mass was around particularly self-referential statements. So if I say this sentence is false, it's self-referential and if it is false, then it's true, but if it's true, then it's false and you get this kind of weird self-referential contradictions.Adam Kucharski (31:13):And so, one of the theories about Gödel was that in the Constitution, it wasn't that there was a kind of rule for someone can become a dictator, but rather people can use the mechanisms within the Constitution to make it easier to make further amendments. And he kind of downward cycle of amendment that he had seen happening in Europe and the run up to the war, and again, because this is never fully documented exactly what he thought, but it's one of the theories that it wouldn't just be outright that it would just be this cycle process of weakening and weakening and weakening and making it easier to add. And actually, when I wrote that, it was all the earlier bits of the book that I drafted, I did sort of debate whether including it I thought, is this actually just a bit in the weeds of American history? And here we are. Yeah, it's remarkable.Eric Topol (32:00):Yeah, yeah. No, I mean I found, it struck me when I was reading this because here back in 1947, there was somebody predicting that this could happen based on some, if you want to call it loopholes if you will, or the ability to change things, even though you would've thought otherwise that there wasn't any possible capability for that to happen. Now, one of the things I thought was a bit contradictory is two parts here. One is from Angus Deaton, he wrote, “Gold standard thinking is magical thinking.” And then the other is what you basically are concluding in many respects. “To navigate proof, we must reach into a thicket of errors and biases. We must confront monsters and embrace uncertainty, balancing — and rebalancing —our beliefs. We must seek out every useful fragment of data, gather every relevant tool, searching wider and climbing further. Finding the good foundations among the bad. Dodging dogma and falsehoods. Questioning. Measuring. Triangulating. Convincing. Then perhaps, just perhaps, we'll reach the truth in time.” So here you have on the one hand your search for the truth, proof, which I think that little paragraph says it all. In many respects, it sums up somewhat to the work that you review here and on the other you have this Nobel laureate saying, you don't have to go to extremes here. The enemy of good is perfect, perhaps. I mean, how do you reconcile this sense that you shouldn't go so far? Don't search for absolute perfection of proof.Adam Kucharski (33:58):Yeah, I think that encapsulates a lot of what the book is about, is that search for certainty and how far do you have to go. I think one of the things, there's a lot of interesting discussion, some fascinating papers around at what point do you use these studies? What are their flaws? But I think one of the things that does stand out is across fields, across science, medicine, even if you going to cover law, AI, having these kind of cookie cutter, this is the definitive way of doing it. And if you just follow this simple rule, if you do your p-value, you'll get there and you'll be fine. And I think that's where a lot of the danger is. And I think that's what we've seen over time. Certain science people chasing certain targets and all the behaviors that come around that or in certain situations disregarding valuable evidence because you've got this kind of gold standard and nothing else will do.Adam Kucharski (34:56):And I think particularly in a crisis, it's very dangerous to have that because you might have a low level of evidence that demands a certain action and you almost bias yourself towards inaction if you have these kind of very simple thresholds. So I think for me, across all of these stories and across the whole book, I mean William Gosset who did a lot of pioneering work on statistical experiments at Guinness in the early 20th century, he had this nice question he sort of framed is, how much do we lose? And if we're thinking about the problems, there's always more studies we can do, there's always more confidence we can have, but whether it's a patient we want to treat or crisis we need to deal with, we need to work out actually getting that level of proof that's really appropriate for where we are currently.Eric Topol (35:49):I think exceptionally important that there's this kind of spectrum or continuum in following science and search for truth and that distinction, I think really nails it. Now, one of the things that's unique in the book is you don't just go through all the different types of how you would get to proof, but you also talk about how the evidence is acted on. And for example, you quote, “they spent a lot of time misinforming themselves.” This is the whole idea of taking data and torturing it or using it, dredging it however way you want to support either conspiracy theories or alternative facts. Basically, manipulating sometimes even emasculating what evidence and data we have. And one of the sentences, or I guess this is from Sir Francis Bacon, “truth is a daughter of time”, but the added part is not authority. So here we have our president here that repeats things that are wrong, fabricated or wrong, and he keeps repeating to the point that people believe it's true. But on the other hand, you could say truth is a daughter of time because you like to not accept any truth immediately. You like to see it get replicated and further supported, backed up. So in that one sentence, truth is a daughter of time not authority, there's the whole ball of wax here. Can you take us through that? Because I just think that people don't understand that truth being tested over time, but also manipulated by its repetition. This is a part of the big problem that we live in right now.Adam Kucharski (37:51):And I think it's something that writing the book and actually just reflecting on it subsequently has made me think about a lot in just how people approach these kinds of problems. I think that there's an idea that conspiracy theorists are just lazy and have maybe just fallen for a random thing, but talking to people, you really think about these things a lot more in the field. And actually, the more I've ended up engaging with people who believe things that are just outright unevidenced around vaccines, around health issues, they often have this mountain of papers and data to hand and a lot of it, often they will be peer reviewed papers. It won't necessarily be supporting the point that they think it's supports.Adam Kucharski (38:35):But it's not something that you can just say everything you're saying is false, that there's actually often a lot of things that have been put together and it's just that leap to that conclusion. I think you also see a lot of scientific language borrowed. So I gave a talker early this year and it got posted on YouTube. It had conspiracy theories it, and there was a lot of conspiracy theory supporters who piled in the comments and one of the points they made is skepticism is good. It's the kind of law society, take no one's word for it, you need this. We are the ones that are kind of doing science and people who just assume that science is settled are in the wrong. And again, you also mentioned that repetition. There's this phenomenon, it's the illusory truth problem that if you repeatedly tell someone someone's something's false, it'll increase their belief in it even if it's something quite outrageous.Adam Kucharski (39:27):And that mimics that scientific repetition because people kind of say, okay, well if I've heard it again and again, it's almost like if you tweak these as mini experiments, I'm just accumulating evidence that this thing is true. So it made me think a lot about how you've got essentially a lot of mimicry of the scientific method, amount of data and how you present it and this kind of skepticism being good, but I think a lot of it comes down to as well as just looking at theological flaws, but also ability to be wrong in not actually seeking out things that confirm. I think all of us, it's something that I've certainly tried to do a lot working on emergencies, and one of the scientific advisory groups that I worked on almost it became a catchphrase whenever someone presented something, they finished by saying, tell me why I'm wrong.Adam Kucharski (40:14):And if you've got a variant that's more transmissible, I don't want to be right about that really. And it is something that is quite hard to do and I found it is particularly for something that's quite high pressure, trying to get a policymaker or someone to write even just non-publicly by themselves, write down what you think's going to happen or write down what would convince you that you are wrong about something. I think particularly on contentious issues where someone's got perhaps a lot of public persona wrapped up in something that's really hard to do, but I think it's those kind of elements that distinguish between getting sucked into a conspiracy theory and really seeking out evidence that supports it and trying to just get your theory stronger and stronger and actually seeking out things that might overturn your belief about the world. And it's often those things that we don't want overturned. I think those are the views that we all have politically or in other ways, and that's often where the problems lie.Eric Topol (41:11):Yeah, I think this is perhaps one of, if not the most essential part here is that to try to deal with the different views. We have biases as you emphasized throughout, but if you can use these different types of proof to have a sound discussion, conversation, refutation whereby you don't summarily dismiss another view which may be skewed and maybe spurious or just absolutely wrong, maybe fabricated whatever, but did you can engage and say, here's why these are my proof points, or this is why there's some extent of certainty you can have regarding this view of the data. I think this is so fundamental because unfortunately as we saw during the pandemic, the strident minority, which were the anti-science, anti-vaxxers, they were summarily dismissed as being kooks and adopting conspiracy theories without the right engagement and the right debates. And I think this might've helped along the way, no less the fact that a lot of scientists didn't really want to engage in the first place and adopt this methodical proof that you've advocated in the book so many different ways to support a hypothesis or an assertion. Now, we've covered a lot here, Adam. Have I missed some central parts of the book and the effort because it's really quite extraordinary. I know it's your third book, but it's certainly a standout and it certainly it's a standout not just for your books, but books on this topic.Adam Kucharski (43:13):Thanks. And it's much appreciated. It was not an easy book to write. I think at times, I kind of wondered if I should have taken on the topic and I think a core thing, your last point speaks to that. I think a core thing is that gap often between what convinces us and what convinces someone else. I think it's often very tempting as a scientist to say the evidence is clear or the science has proved this. But even on something like the vaccines, you do get the loud minority who perhaps think they're putting microchips in people and outlandish views, but you actually get a lot more people who might just have some skepticism of pharmaceutical companies or they might have, my wife was pregnant actually at the time during Covid and we waited up because there wasn't much data on pregnancy and the vaccine. And I think it's just finding what is convincing. Is it having more studies from other countries? Is it understanding more about the biology? Is it understanding how you evaluate some of those safety signals? And I think that's just really important to not just think what convinces us and it's going to be obvious to other people, but actually think where are they coming from? Because ultimately having proof isn't that good unless it leads to the action that can make lives better.Eric Topol (44:24):Yeah. Well, look, you've inculcated my mind with this book, Adam, called Proof. Anytime I think of the word proof, I'm going to be thinking about you. So thank you. Thanks for taking the time to have a conversation about your book, your work, and I know we're going to count on you for the astute mathematics and analysis of outbreaks in the future, which we will see unfortunately. We are seeing now, in fact already in this country with measles and whatnot. So thank you and we'll continue to follow your great work.**************************************Thanks for listening, watching or reading this Ground Truths podcast/post.If you found this interesting please share it!That makes the work involved in putting these together especially worthwhile.I'm also appreciative for your subscribing to Ground Truths. All content —its newsletters, analyses, and podcasts—is free, open-access. I'm fortunate to get help from my producer Jessica Nguyen and Sinjun Balabanoff for audio/video tech support to pull these podcasts together for Scripps Research.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years.A bit of an update on SUPER AGERSMy book has been selected as a Next Big Idea Club winner for Season 26 by Adam Grant, Malcolm Gladwell, Susan Cain, and Daniel Pink. This club has spotlighted the most groundbreaking nonfiction books for over a decade. As a winning title, my book will be shipped to thousands of thoughtful readers like you, featured alongside a reading guide, a "Book Bite," Next Big Idea Podcast episode as well as a live virtual Q&A with me in the club's vibrant online community. If you're interested in joining the club, here's a promo code SEASON26 for 20% off at the website. SUPER AGERS reached #3 for all books on Amazon this week. This was in part related to the segment on the book on the TODAY SHOW which you can see here. Also at Amazon there is a remarkable sale on the hardcover book for $10.l0 at the moment for up to 4 copies. Not sure how long it will last or what prompted it.The journalist Paul von Zielbauer has a Substack “Aging With Strength” and did an extensive interview with me on the biology of aging and how we can prevent the major age-related diseases. Here's the link. Get full access to Ground Truths at erictopol.substack.com/subscribe

On The Wire Adam Howe and Kevin Hasting analyze the FAAB-related news of the week and discuss some players to pick up during Sunday's FAAB run.Chandler Simpson recalled by TB, Kameron Misner optioned to Triple-ALuisangel Acuña, Francisco Alvarez, and Jared Young optioned to Triple-A by the Mets. Mark Vientos returned Friday (DH hitting 6th)Jeimer Candelario designated for assignment by the RedsChase Burns makes MLB debut for CINJake Fraley to IL, Austin Hays activatedTyler Fitzgerald optioned to Triple-A by the GiantsCorbin Carroll to IL, Jake McCarthy recalledDiamondbacks place Ildemaro Vargas on the IL and call up Blaze AlexanderJordan Lawler injured his hamstring, will be shut down for another month in AAABen Brown optioned to Triple-AGriffin Canning left Thursday's game early with ankle injury. Opening for Mets' rotation?Wyatt Langford to IL for TEX, backdated. Expected back in a weekBryce Harper is expected back during next week's homestand. Who will lose out with his return?Power (HR, RBI)Wenceel Perez (33% OC); Andrew Benintendi (98%, 29%); Gary Sanchez (97%, 51%) Speed (R, SB)Zach McKinstry (93%, 48%); Isaac Collins (67%, 6%)Opportunity (AB, AVG)Mike Tauchman (40%, 4%); Lenyn Sosa (25%, 0%); Jake Meyers (98%, 88%)Pitching Volume (Wins, K's)Trevor Rogers (53%, 7%); Charlie Morton (62% OC); Tomoyuki Sugano (93%, 77%); Richard Fitts (37%, 3%); Eric Lauer (49%, 7%); Slade Cecconi (90%, 37%); David Festa (63%, 33%); Simeon Woods-Richardson (16%, 1%); Tyler Anderson (63%, 14%); Emerson Hancock (42%, 4%); Patrick Corbin (72%, 12%); Bryce Elder (58%, 22%); Chase Burns (0%); Andrew Heaney (95%, 50%); Erick Fedde (98%, 59%); Andre Pallante (67%, 3%); Ryne Nelson (97%, 64%); Randy Vasquez (19%, 3%), Stephen Kolek (56%, 15%), Yu Darvish (84%, 15%)Ratios (ERA, WHIP)Yariel Rodriguez; Braydon FisherSavesGrant TaylorWild CardAndrew Painter  Join Our Discord & Support The Show: PL+ | PL Pro - Get 15% off Yearly with code PODCASTProud member of the Pitcher List Fantasy Baseball Podcast Network

What are the latest trends in large-scale cyberattacks, and how can individuals help prevent them?Large-scale cyberattacks, especially Distributed Denial of Service (DDoS), are growing in both scale and sophistication. One recent attack hit 7.3 Tbps, unleashing 37.4 TB of junk traffic in 45 seconds. These attacks often harness botnets made up of compromised Internet of Things (IoT) devices—like home routers or cameras—that have default credentials or unpatched software.How to help prevent this:Change default passwords on IoT devicesRegularly update firmwareDisable unused services (e.g., Telnet)Use firewalls and segment your networkHow do smart TVs and other smart devices compromise privacy, and what's being done?Smart devices like TVs and speakers often use Automatic Content Recognition (ACR) to monitor what you're watching and send this data to manufacturers or advertisers—often without clear consent. This data fuels detailed user profiling and cross-device tracking.In response, the UK's Information Commissioner's Office (ICO) now requires manufacturers to ensure transparency, secure data handling, and routine data deletion—or face enforcement. Consumers can protect themselves by disabling ACR (e.g., SyncPlus on Samsung, Live Plus on LG) and reviewing privacy settings.What are the current limitations of LLM-based AI in enterprise settings?A Salesforce-led study found that large language model (LLM) AI agents succeed at only 58% of basic CRM tasks and just 35% of multi-step ones. More concerning, they exhibit poor confidentiality awareness. Prompting helps slightly but often hurts task accuracy. Current benchmarks fail to assess sensitivity to confidential data, raising red flags for enterprise use without rigorous testing.What are the geopolitical implications of AI and cyber operations?AI and cyber tools are shaping geopolitical strategies. The U.S. accuses Chinese AI firm DeepSeek of aiding military intelligence and bypassing export controls. Chinese law further mandates data sharing with its government, raising global privacy concerns. Meanwhile, cyberattacks are weaponized to disrupt infrastructure and spread disinformation—as seen in Iran's state TV hijacking and a $90M crypto exchange hack.How do data brokers threaten personal safety, and what can you do?Data brokers compile and sell personal data—including home addresses—without vetting buyers. This can lead to stalking or worse, as shown in the murder of Rep. Melissa Hortman, allegedly found via a “people search” site.The U.S. lacks federal regulation, but California's "Delete Act" is a step forward. Until broader laws are in place, individuals must manually opt out of data broker sites or hire services to assist in removing their information.How are ransomware groups evolving?Groups like Qilin are getting more professional. Their “Call a Lawyer” service gives affiliates legal guidance to classify stolen data, assess damages, and negotiate ransoms more effectively—maximizing economic pressure on victims. It's a troubling move toward organized, businesslike cybercrime.Why is ACR in smart TVs a privacy issue?ACR continuously scans all video content viewed on your TV—even from HDMI devices—and sends data to third parties. It enables:Tracking without consentData monetization for targeted adsCross-device profilingPotential security risks from unmaintained TV firmwareWhy should you secure IoT devices?Unpatched IoT devices can be infected and used in global botnet attacks. By securing your devices, you're not only protecting yourself but also helping reduce the scale of global cyber threats.

Can food heal? When it comes to tuberculosis, the answer is yes.We often think of food as comfort, culture, or even celebration—but what if it could also be medicine? In this episode, we explore the critical yet often overlooked link between nutrition and TB—how what's on the plate can impact recovery, immunity, and even survival.Joining us is Prachi Shukla, Country Director at World Health Partners, who brings her on-ground experience and expertise to this powerful conversation.We cover:• How poor nutrition increases vulnerability to TB• Why food plays a key role in recovery and treatment success• What local, affordable foods support healing• The intersection of poverty, illness, and access to nutrition• How families and frontline workers can take small but meaningful actionsAbout Nutrition Every Day: It is a special podcast series by The Good Sight and Rise Against Hunger India, bringing sharp, grounded insights on health and nutrition. For feedback or to participate, write to us at ⁠contact@thegoodsight.org⁠CreditsHost: Shreya MResearch: Alisha CShow Artwork: Rajnikant SProduced by: The Good SightConcept: The Good Sight & Rise Against Hunger India#NutritionEveryDay #FoodAsMedicine #Tuberculosis #PublicHealth #TheGoodSight #RiseAgainstHungerIndia #HealthForAll

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

*This podcast is sponsored by AXA Farm Insurance.Charles O'Donnell, Aisling O'Brien and Kathleen O Sullivan bring you the biggest stories of the week in Irish agriculture from Agriland, which this week includes:Average family farm income up by 87% in 2024;No decision yet on next CAP budget;IFA wants CAP scheme for active farmers;Macra calls for inclusion of installation aid in new CAP;Over 1,600 farmers still awaiting 2024 ACRES advance payments;Cabinet approval to address increasing bovine TB levels;Agri-food sector voices concerns on proposed employment permit salary hikes;Responsibility for dog control transferred to DAFM.Don't forget to rate, review and follow The Farming Week, Agriland's weekly review of Irish agriculture, and visit Agriland.ie for more. 

Uma nova ferramenta usada para dar golpes vem aparecendo com mais frequência no Brasil: as estações rádio base falsas. Em resumo, as ERBs bloqueiam o sinal das operadoras e usam a rede 2G para disparar SMSs com phishing.No episódio de hoje a explica melhor como funcionam esses golpes e o que é possível fazer para se proteger. Dá o play e vem com a gente!Mande seu recadoGrupos da Caixa Postal do Tecnocast: Telegram: t.me/caixapostaltecnocast WhatsApp: tbnet.me/caixapostaltecnocast Você pode mandar comentários (inclusive em áudio, vai que você aparece no Tecnocast?), dúvidas, críticas e sugestões. Participe!Se preferir, você pode se comunicar conosco pela Comunidade e através do e-mail tecnocast@tecnoblog.net.Entre também nos Canais do TB no WhatsApp Canal do Tecnoblog Canal do Achados do TB CréditosProdução: Josué de OliveiraEdição e sonorização: Ariel LiborioArte da capa: Vitor Pádua

This week we sat down with Doug Foley Jr. to talk about his recent success at the TB 250k. We then got deep into the newest IHRA news. How are the races going to work? What's the run order? What are Doug's personal thoughts on the series? All this and more in Episode 197 of the Going Bracket Racing Podcast!Email us at GoingBracketRacing@gmail.com to learn how you can support the show!

The boys are back recapping the player movement from the NFBC Main Event Week 14 FAAB. Plus we look at the possible first round of 2026 draftsExcuse the last audio post. Was a problem with the audio. I deleted itClosersKerkering, Halvorsen, Grant TaylorPower Bats - Toglia - did we just pay for his best week?Stanton - only 81% added?House - .304, 13 HR, 42 run, 41 RBI at AAA.Moniak - 4 HR, 9 RBI last week, but lots of LHP upcomingSanchez - Adley on IL, ton of catcher injuries this weekSPs - Sheehan - back to AAA, but for how long?Jacob Lopez - @ DET this week, 2-step @ TB, vs. SF next week.  Is this for real?Catchers - Adley, Moreno, Herrera, Alvarez owners were all looking for catchers this weekPedro PagesJoey BartLuis TorrensVictor CaratiniLesser added catchers - Austin Wynns, Edgar Quero, Liam Hicks, Patrick BaileyStarting Pitchers - finally a good week to stream 2-start SPs, but are you playing with fire?Janson JunkDidier FuentesEric Lauer - 2-stepTrevor Rogers - 8 shutout tonight wtf? 2-stepJ. Wrobleski - 2-stepGustoKolek 2-stepFitts Parker 2- stepBatsIsaac CollinsDavid HamiltonYazJoey OrtizCanzoneCasey Schmitt⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PullHitter merch is here! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Welcome to the PullHitter Podcast, your destination for actionable resources and tools to grind your way to ultimate fantasy baseball success.Support my work and join the Pull Hitter Patreon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-Access to lively Discord with highly active members sharing player evaluations, draft boards and strategies..get a leg up on your league mates!-Player Breakdowns series in audio and video form-Draft recaps from me-additional Launch Angle episodes-additional Guest episodes-ad free listening-Much more!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/user?u=32383693&utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_link⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow on twitter: @pullhitterpod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/PullHitterPod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ @deadpullhitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/deadpullhitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email : pullhitterpodcast@gmail.com Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠pullhitter.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My link tree with all of my links in one spot:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/pullhitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Also check out me cohosting the Launch Angle Podcast with Jeff Zimmerman and Rob Silver!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anchor.fm/robe

In this week's episode, the guys recap the NBA Finals, take a look at some big off-season moves that have already taken place, and the sale of the Los Angeles Lakers.Check us out on Instagram: https://www.instagram.com/sneaksandstats/We're also on YouTube: https://www.youtube.com/channel/UChfjqV40wCrqVFIqlfbnt_ABuy a pair for yourself:Nike x Patta Air Max 90 Waves "Cyber" - https://stockx.com/nike-air-max-90-sp-patta-waves-cyberConverse 1908 Naut-1 x Le Fleur - https://www.converse.com/shop/p/converse-1908-naut-1-unisex-low-top-shoe/A16308C.html?dwvar_A16308C_color=cannoli%20cream%2Fstone%20green&dwvar_A16308C_width=standard&styleNo=A16308C&cgid=Converse 1908 Jogger x Le Fleur - https://www.converse.com/shop/p/converse-1908-jogger-unisex-low-top-shoe/A16192MP.html?dwvar_A16192MP_color=quiet%20tide%2Fstarlight%20blue&dwvar_A16192C_width=standardNike KD 18 "New Timeline" - https://www.nike.com/t/kd18-new-timeline-basketball-shoes-sBxXXKpD/HV1993-301Adidas Harden Vol. 9 "Pinky and the Brain" - https://stockx.com/adidas-harden-vol-9-jalen-williams-white-lucid-lime-pinkNike Ja 1 TB - https://www.dickssportinggoods.com/p/nike-ja-1-basketball-shoes-24nikaj1tbblwhtxxmnk/24nikaj1tbblwhtxxmnk?sku=25421997&srsltid=AfmBOoo4DZ9E2jGpGaa-4ieopKCd6fzO7wgp51v4xXn8IFmuZk_82Lq3AEo&gQT=2

Since the 1800s, tuberculosis (TB) has been responsible for an estimated 1 billion deaths. In New Zealand today, we don't get many cases of TB, but worldwide it is the leading infectious disease killer. In the early 1900s a TB vaccine was developed. Called the BCG vaccine, it's still used today. While it is the best TB vaccine we have, it's not actually great at preventing TB infection, only providing some protection for the youngest of patients. However, scientists have discovered that the BCG vaccine can boost people's immune systems in other ways. Now researchers at the Malaghan Institute in Wellington are investigating these findings further. Sign up to the Our Changing World monthly newsletter for episode backstories, science analysis and more.Guests:Dr Kerry Hilligan, Malaghan InstituteRebecca Palmer, Malaghan InstituteLearn more:In 2017, Alison Ballance reported on the looming antimicrobial resistance crisis, with drug-resistant TB part of the problem.Other Our Changing World episodes about research at the Malaghan Institute include this 2024 episode on a new way to target rising stomach cancer rates, and this 2022 episode on next-generation cancer therapies.In 2021, Claire Concannon covered mRNA vaccine technology.The What if...? Genomics in Aotearoa series explores the different ways genomics is transforming different sectors, including infectious disease medicine.Go to this episode on rnz.co.nz for more details

Celé PREMIUM VIDEO nájdeš tu

In this powerful episode of the Tick Boot Camp Podcast, we welcome Austin Shubert, a 27-year-old outdoorsman, hunter, and field technician from Zebulon, Georgia. He shares his deeply personal and emotional journey from vibrant health to chronic illness and back toward recovery. Raised in the woods, surrounded by ticks since childhood, Austin never imagined that a single tick bite could change his life.

She once woke up to alcohol and ended her day the same way. From battling jaundice, brain TB, and cancer to enduring bariatric surgery, Sunaina Roshan has lived through what most wouldn't survive.But everything changed after one bold decision: healing her gut.In this episode, she reveals how a structured gut reset transformed her energy, immunity, mood—and mindset. It's a raw, no-fluff conversation about reclaiming health, finding hope, and rebuilding your life when all seems lost.If you're stuck in a health rut or looking for a wake-up call, this is your sign.Full episodeImportant links:⁠⁠⁠⁠⁠⁠⁠⁠⁠Ryan Fernando App⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Diet plan ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Blood test⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cancer screening⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Studies of the podcast⁠⁠⁠⁠⁠Socials:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link tree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠Products to purchase:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Collagen ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 1500g⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 750g ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Books ⁠⁠⁠⁠⁠Find Sunaina here: Instagram Facebook X LinkedIn Time stamps:00:00 Trailer1:42 – Introduction3:10 – The Power of Mindset4:14 – Mantra for a Strong Mindset5:55 – Sunaina's Inspiration6:30 – Understanding Gut Microbiome Testing12:21 – First Sign of Change14:06 – Why You Crave Junk Food14:30 – The Secret to Newfound Stamina21:16 – Message to Women Battling Cancer22:49 – Advice to a Young Sunaina23:44 – Diet Before Cancer26:07 – The Importance of Fitness30:39 – Liver Health & Wellness33:30 – Wake-Up Call Moment38:01 – Foods That Help the Liver Regenerate39:54 – The Importance of Cell Turnover41:57 – The Food-Mood Connection42:24 – Chamomile Tea & Better Sleep48:18 – Reversing Fatty Liver47:50 – The Role of Discipline52:29 – Sunaina's Daily Routine58:06 – Advice for Women Struggling with Health1:01:55 – Rapid Fire Round1:11:40 – Overcoming Brain TB1:14:50 – Outro

Hosťom relácie Dírerov filter bol emeritný arcibiskup Róbert Bezák. Vyštudoval Teologickú fakultu v Bratislave. Za komunistického režimu bol členom rehole napriek tomu, že členstvo v reholiach bolo zakázané. ŠtB sa ho snažila získať na spoluprácu, ktorú však odmietol. Po vysviacke pôsobil ako kaplán v Brezne. V Ríme študoval morálnu teológiu. Pôsobil aj v kláštore redemptoristov v talianskom Bussolengu. Neskôr sa stal arcibiskupom Trnavskej diecézy, na miesto nastúpil po odchode Jána Sokola. V tejto funkcii upozornil Vatikán na problémy hospodárenia v arcidiecéze a čudné nakladanie s cirkevným majetkom. Róbert Bezák rozbehol aj projekt mapovania spolupráce kléru trnavskej arcidiecézy s komunistickou ŠtB. Po tlakoch ho pápež Benedikt XVI. odvolal. Na jeho podporu sa konali viaceré zhromaždenia. Pápež František mu nakoniec biskupský prsteň vrátil. Róbert Bezák sa pravidelne angažuje v boji za demokraciu, slobodu slova a podporil aj protesty Za slušné Slovensko.

*This podcast is sponsored by AXA Farm Insurance.Charles O'Donnell and Aisling O'Brien bring you the biggest stories of the week in Irish agriculture from Agriland, which this week includes:TB programme expected to cost €130m this year;Processors announce May milk prices;Poultry broiler sector removed from VAT flat rate;All Straw Incorporation Measure applicants accepted;Concerns over Boortmalt malting barley contracts;RSA ‘considering' driving test for working vehicles;Don't forget to rate, review and follow The Farming Week, Agriland's weekly review of Irish agriculture, and visit Agriland.ie for more. 

In this episode of Going Bracket Racing Live, we talk about the TB 250k and how these footbrakers keep showing up in top bulb finals. Is bottom bulb more difficult? If so, why do we keep seeing bottom bulbers in major top bulb finals?Get GBR Merchhttps://eighthmileapparel.com/collections/going-bracket-racing

In the final installment of this season of Titans of Science, Chris Smith speaks with Sharon Peacock, one of the UK's leading voices in infectious disease research. She is best known for her work on whole genome sequencing of pathogens such as MRSA and SARS CoV-2, and studies of antimicrobial resistance... Like this podcast? Please help us by supporting the Naked Scientists

Host: Darryl S. Chutka, M.D. Guest: John W. Wilson, M.D. Tuberculosis remains a significant health concern. Globally, in 2023, an estimated 10 million individuals developed active tuberculosis and over one million died of the disease. In the U.S., just under 10, 000 individuals in the U.S. were diagnosed with TB, representing an increase over 2022. While tuberculosis remains a treatable disease, it's important to suspect and recognize those who may have it. A class 5 tuberculosis case is part of a TB classification system and refers to a suspected tuberculosis infection that requires further investigation. Symptoms may or may not be present and these patients may have an active TB case that could be contagious. This podcast is about class 5 tuberculosis cases, and my guest is infectious disease specialist, John W. Wilson, M.D., from the Mayo Clinic. Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts

In this episode of the Ageless Future Podcast, Cade Archibald dives into the science and strategy behind muscle-building peptides, showcasing real-world success stories from East West Health. Focusing on peptides like CJC-1295, Ipamorelin, BPC-157, and TB-500, Cade walks listeners through the role of growth hormone secretagogues and regenerative peptides in transforming body composition and enhancing recovery. Highlighting a case study of a 58-year-old male who cut his body fat nearly in half while gaining muscle and energy, the episode underscores the synergy of personalized protocols, clean supplementation, and structured training. Cade also provides practical advice, exercise tips, and a weekly challenge to help listeners begin their own transformation using the tools of modern longevity science. www.agelessfuture.com 

TB is back. His daughter did her think for Atherton track in year one. Vince Marrow is heading to Louisville. The upcoming football season has us all like, Yikes. NBA Finals and more!Become a supporter of this podcast: https://www.spreaker.com/podcast/cats-talk-wednesday--4693915/support.

A Apple apresentou o novo design de todos os seus sistemas operacionais na WWDC 2025. Ele foi chamado Liquid Glass e lembra bastante algumas coisas que a gente já viu ali pelos anos 2000.Além disso tivemos novidades grandes no iPadOS, no que diz respeito à multitarefa. Mas fora isso, o evento parece que deixou um pouquinho a desejar.Mande seu recadoGrupos da Caixa Postal do Tecnocast: Telegram: t.me/caixapostaltecnocast WhatsApp: tbnet.me/caixapostaltecnocast Você pode mandar comentários (inclusive em áudio, vai que você aparece no Tecnocast?), dúvidas, críticas e sugestões. Participe!Se preferir, você pode se comunicar conosco pela Comunidade e através do e-mail tecnocast@tecnoblog.net.Entre também nos Canais do TB no WhatsApp Canal do Tecnoblog Canal do Achados do TB CréditosProdução: Josué de OliveiraEdição e sonorização: Ariel LiborioArte da capa: Vitor Pádua

Think peptides are just the latest hype? Think again. In this episode, Trevor breaks down what peptides actually are (spoiler: they're not magic potions), how they work in your body, and why they can be game-changing—but only after you've nailed the basics. We cover the science behind recovery favorites like BPC-157, TB-500, and CJC-1295, who they're for (and who they're not for), and how to approach supplementation with intention, not desperation. This is your no-fluff guide to smarter healing, faster bounce-backs, and long-term durability.  

Get to know Microsoft's latest Patch Tuesday updates and new features in Windows 11, such as improvements to the Start menu, File Explorer, and Copilot integration. They also cover new AI features coming to the Photos app for Copilot+ PCs and updates to the Microsoft Store. The discussion then shifts to developer conferences like Google I/O and Apple's WWDC, with a focus on their respective AI advancements and product strategies. Plus, the controversy surrounding Microsoft's decision to no longer host its Build conference in Seattle. Don't miss the discussion on the evolving role of the iPad as a potential threat to Surface devices due to recent software enhancements! Windows 11 June Patch Tuesday is here! Big changes for Windows 11 versions 22H2, 23H2, and 24H2 New Start menu finally debuts in Dev and Beta - synchronized again for some reason Copilot+ PCs get Relight feature and natural language search in the Photos app The Microsoft Store gets a major update in the Beta channel And Canary is still a thing, no one knows why Developer conference season draws to a close Build: Protests, problems, and more problems Microsoft pulls out of Seattle permanently Google I/O: Stunning array of AI announcements. But Android 16 is on a weird slow boil after a truncated development cycle Apple WWDC: Apple Intelligence? Look, Liquid Glass! Also, some actual advances across its newly unified platforms Look out Surface: The iPad is a real computer now - And it only took 15 years Microsoft, Google, and Apple all played to their strengths Between Windows 11 2xH2, Android 16, and iOS whatever - do the platform makers even know how to ship software anymore? Xbox Microsoft unveils the first Xbox-branded third-party gaming handheld as part of its Xbox Games Showcase 2025 event - a few interesting things there as well - COD: BO7, Gears remake, Gears v.next delayed to 2026 This heavily modified/optimized version of Windows 11 is coming to more gaming handhelds Looking to the future: What if this is literally the model for future Xbox console hardware? What if the next Xbox was a NUC? More Game Pass titles across platforms for the second half of June You can add 4 TB of storage to your Xbox, but it will cost you dearly Apple loses again in Epic v. Apple, Fortnite can stay in the App Store and developers can stop getting robbed by Apple The Nintendo Switch 2 launched this past week and is apparently the best-selling console of all time at launch PS5 controllers to support multiple Bluetooth connections Tips and Picks Tip of the week: Share Feature, image crunching App pick of the week: Dia Browser RunAs Radio this week: The Case for Telemetry with Liz Fong-Jones Brown liquor pick of the week: Glenlossie 26 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to Windows Weekly at https://twit.tv/shows/windows-weekly Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: uscloud.com 1password.com/windowsweekly

Get to know Microsoft's latest Patch Tuesday updates and new features in Windows 11, such as improvements to the Start menu, File Explorer, and Copilot integration. They also cover new AI features coming to the Photos app for Copilot+ PCs and updates to the Microsoft Store. The discussion then shifts to developer conferences like Google I/O and Apple's WWDC, with a focus on their respective AI advancements and product strategies. Plus, the controversy surrounding Microsoft's decision to no longer host its Build conference in Seattle. Don't miss the discussion on the evolving role of the iPad as a potential threat to Surface devices due to recent software enhancements! Windows 11 June Patch Tuesday is here! Big changes for Windows 11 versions 22H2, 23H2, and 24H2 New Start menu finally debuts in Dev and Beta - synchronized again for some reason Copilot+ PCs get Relight feature and natural language search in the Photos app The Microsoft Store gets a major update in the Beta channel And Canary is still a thing, no one knows why Developer conference season draws to a close Build: Protests, problems, and more problems Microsoft pulls out of Seattle permanently Google I/O: Stunning array of AI announcements. But Android 16 is on a weird slow boil after a truncated development cycle Apple WWDC: Apple Intelligence? Look, Liquid Glass! Also, some actual advances across its newly unified platforms Look out Surface: The iPad is a real computer now - And it only took 15 years Microsoft, Google, and Apple all played to their strengths Between Windows 11 2xH2, Android 16, and iOS whatever - do the platform makers even know how to ship software anymore? Xbox Microsoft unveils the first Xbox-branded third-party gaming handheld as part of its Xbox Games Showcase 2025 event - a few interesting things there as well - COD: BO7, Gears remake, Gears v.next delayed to 2026 This heavily modified/optimized version of Windows 11 is coming to more gaming handhelds Looking to the future: What if this is literally the model for future Xbox console hardware? What if the next Xbox was a NUC? More Game Pass titles across platforms for the second half of June You can add 4 TB of storage to your Xbox, but it will cost you dearly Apple loses again in Epic v. Apple, Fortnite can stay in the App Store and developers can stop getting robbed by Apple The Nintendo Switch 2 launched this past week and is apparently the best-selling console of all time at launch PS5 controllers to support multiple Bluetooth connections Tips and Picks Tip of the week: Share Feature, image crunching App pick of the week: Dia Browser RunAs Radio this week: The Case for Telemetry with Liz Fong-Jones Brown liquor pick of the week: Glenlossie 26 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to Windows Weekly at https://twit.tv/shows/windows-weekly Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: uscloud.com 1password.com/windowsweekly

Get to know Microsoft's latest Patch Tuesday updates and new features in Windows 11, such as improvements to the Start menu, File Explorer, and Copilot integration. They also cover new AI features coming to the Photos app for Copilot+ PCs and updates to the Microsoft Store. The discussion then shifts to developer conferences like Google I/O and Apple's WWDC, with a focus on their respective AI advancements and product strategies. Plus, the controversy surrounding Microsoft's decision to no longer host its Build conference in Seattle. Don't miss the discussion on the evolving role of the iPad as a potential threat to Surface devices due to recent software enhancements! Windows 11 June Patch Tuesday is here! Big changes for Windows 11 versions 22H2, 23H2, and 24H2 New Start menu finally debuts in Dev and Beta - synchronized again for some reason Copilot+ PCs get Relight feature and natural language search in the Photos app The Microsoft Store gets a major update in the Beta channel And Canary is still a thing, no one knows why Developer conference season draws to a close Build: Protests, problems, and more problems Microsoft pulls out of Seattle permanently Google I/O: Stunning array of AI announcements. But Android 16 is on a weird slow boil after a truncated development cycle Apple WWDC: Apple Intelligence? Look, Liquid Glass! Also, some actual advances across its newly unified platforms Look out Surface: The iPad is a real computer now - And it only took 15 years Microsoft, Google, and Apple all played to their strengths Between Windows 11 2xH2, Android 16, and iOS whatever - do the platform makers even know how to ship software anymore? Xbox Microsoft unveils the first Xbox-branded third-party gaming handheld as part of its Xbox Games Showcase 2025 event - a few interesting things there as well - COD: BO7, Gears remake, Gears v.next delayed to 2026 This heavily modified/optimized version of Windows 11 is coming to more gaming handhelds Looking to the future: What if this is literally the model for future Xbox console hardware? What if the next Xbox was a NUC? More Game Pass titles across platforms for the second half of June You can add 4 TB of storage to your Xbox, but it will cost you dearly Apple loses again in Epic v. Apple, Fortnite can stay in the App Store and developers can stop getting robbed by Apple The Nintendo Switch 2 launched this past week and is apparently the best-selling console of all time at launch PS5 controllers to support multiple Bluetooth connections Tips and Picks Tip of the week: Share Feature, image crunching App pick of the week: Dia Browser RunAs Radio this week: The Case for Telemetry with Liz Fong-Jones Brown liquor pick of the week: Glenlossie 26 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to Windows Weekly at https://twit.tv/shows/windows-weekly Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: uscloud.com 1password.com/windowsweekly

Get to know Microsoft's latest Patch Tuesday updates and new features in Windows 11, such as improvements to the Start menu, File Explorer, and Copilot integration. They also cover new AI features coming to the Photos app for Copilot+ PCs and updates to the Microsoft Store. The discussion then shifts to developer conferences like Google I/O and Apple's WWDC, with a focus on their respective AI advancements and product strategies. Plus, the controversy surrounding Microsoft's decision to no longer host its Build conference in Seattle. Don't miss the discussion on the evolving role of the iPad as a potential threat to Surface devices due to recent software enhancements! Windows 11 June Patch Tuesday is here! Big changes for Windows 11 versions 22H2, 23H2, and 24H2 New Start menu finally debuts in Dev and Beta - synchronized again for some reason Copilot+ PCs get Relight feature and natural language search in the Photos app The Microsoft Store gets a major update in the Beta channel And Canary is still a thing, no one knows why Developer conference season draws to a close Build: Protests, problems, and more problems Microsoft pulls out of Seattle permanently Google I/O: Stunning array of AI announcements. But Android 16 is on a weird slow boil after a truncated development cycle Apple WWDC: Apple Intelligence? Look, Liquid Glass! Also, some actual advances across its newly unified platforms Look out Surface: The iPad is a real computer now - And it only took 15 years Microsoft, Google, and Apple all played to their strengths Between Windows 11 2xH2, Android 16, and iOS whatever - do the platform makers even know how to ship software anymore? Xbox Microsoft unveils the first Xbox-branded third-party gaming handheld as part of its Xbox Games Showcase 2025 event - a few interesting things there as well - COD: BO7, Gears remake, Gears v.next delayed to 2026 This heavily modified/optimized version of Windows 11 is coming to more gaming handhelds Looking to the future: What if this is literally the model for future Xbox console hardware? What if the next Xbox was a NUC? More Game Pass titles across platforms for the second half of June You can add 4 TB of storage to your Xbox, but it will cost you dearly Apple loses again in Epic v. Apple, Fortnite can stay in the App Store and developers can stop getting robbed by Apple The Nintendo Switch 2 launched this past week and is apparently the best-selling console of all time at launch PS5 controllers to support multiple Bluetooth connections Tips and Picks Tip of the week: Share Feature, image crunching App pick of the week: Dia Browser RunAs Radio this week: The Case for Telemetry with Liz Fong-Jones Brown liquor pick of the week: Glenlossie 26 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to Windows Weekly at https://twit.tv/shows/windows-weekly Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: uscloud.com 1password.com/windowsweekly

Episodio 322.En el Emoji Motel hay un problema espacial giroscópico que es apenas el doble de lo que yo tenía en un momento muy desafortunado, porque era un poquito esquizofrénico y era de 1m, en vez de 2m por culpa de un relojón gigantesco que se ve horroroso ¿Fue Shakira o no fue Shakira?

Get to know Microsoft's latest Patch Tuesday updates and new features in Windows 11, such as improvements to the Start menu, File Explorer, and Copilot integration. They also cover new AI features coming to the Photos app for Copilot+ PCs and updates to the Microsoft Store. The discussion then shifts to developer conferences like Google I/O and Apple's WWDC, with a focus on their respective AI advancements and product strategies. Plus, the controversy surrounding Microsoft's decision to no longer host its Build conference in Seattle. Don't miss the discussion on the evolving role of the iPad as a potential threat to Surface devices due to recent software enhancements! Windows 11 June Patch Tuesday is here! Big changes for Windows 11 versions 22H2, 23H2, and 24H2 New Start menu finally debuts in Dev and Beta - synchronized again for some reason Copilot+ PCs get Relight feature and natural language search in the Photos app The Microsoft Store gets a major update in the Beta channel And Canary is still a thing, no one knows why Developer conference season draws to a close Build: Protests, problems, and more problems Microsoft pulls out of Seattle permanently Google I/O: Stunning array of AI announcements. But Android 16 is on a weird slow boil after a truncated development cycle Apple WWDC: Apple Intelligence? Look, Liquid Glass! Also, some actual advances across its newly unified platforms Look out Surface: The iPad is a real computer now - And it only took 15 years Microsoft, Google, and Apple all played to their strengths Between Windows 11 2xH2, Android 16, and iOS whatever - do the platform makers even know how to ship software anymore? Xbox Microsoft unveils the first Xbox-branded third-party gaming handheld as part of its Xbox Games Showcase 2025 event - a few interesting things there as well - COD: BO7, Gears remake, Gears v.next delayed to 2026 This heavily modified/optimized version of Windows 11 is coming to more gaming handhelds Looking to the future: What if this is literally the model for future Xbox console hardware? What if the next Xbox was a NUC? More Game Pass titles across platforms for the second half of June You can add 4 TB of storage to your Xbox, but it will cost you dearly Apple loses again in Epic v. Apple, Fortnite can stay in the App Store and developers can stop getting robbed by Apple The Nintendo Switch 2 launched this past week and is apparently the best-selling console of all time at launch PS5 controllers to support multiple Bluetooth connections Tips and Picks Tip of the week: Share Feature, image crunching App pick of the week: Dia Browser RunAs Radio this week: The Case for Telemetry with Liz Fong-Jones Brown liquor pick of the week: Glenlossie 26 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to Windows Weekly at https://twit.tv/shows/windows-weekly Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: uscloud.com 1password.com/windowsweekly

Canadian journalist Nora Loreto reads the latest headlines for Tuesday, June 10, 2025.TRNN has partnered with Loreto to syndicate and share her daily news digest with our audience. Tune in every morning to the TRNN podcast feed to hear the latest important news stories from Canada and worldwide.Find more headlines from Nora at Sandy & Nora Talk Politics podcast feed.Help us continue producing radically independent news and in-depth analysis by following us and becoming a monthly sustainer.Sign up for our newsletterLike us on FacebookFollow us on TwitterDonate to support this podcast

Is your quest for peak performance lost in a sea of biohacking fads and conflicting advice? In a world saturated with quick fixes and miracle cures, discerning genuine science from fleeting trends can feel like navigating a minefield. Many embark on their optimization journey armed with popular advice, only to find themselves investing time, energy, and resources into strategies that yield minimal returns or, worse, prove counterproductive. The allure of the "next big thing" often overshadows the foundational pillars of true health and vitality, leaving many feeling frustrated and no closer to their goals.Enter Dr. Neil Paulvin, a renowned physician specializing in human performance and longevity for high-achievers, from CEOs to elite athletes. In this eye-opening episode of MindHack, Dr. Paulvin joins us to dismantle the myths and cut through the noise. He provides a masterclass in true health optimization, revealing which popular biohacks stand up to scientific scrutiny and which are merely hype. If you're ready to move beyond the fads and build a resilient foundation for lasting peak performance, this conversation is your tactical blueprint.ℹ️ About the GuestDr. Neil Paulvin is a leading physician in longevity and human performance. He works with CEOs, Fortune 500 executives, and professional athletes to help them achieve peak physical and mental output. Dr. Paulvin focuses on a comprehensive, science-backed approach, integrating foundational health principles with cutting-edge advanced therapies, always emphasizing personalized protocols based on in-depth biomarker analysis and individual goals.  Website: Dr. Neil Paulvin: Functional Medicine & Integrated Manual Theraphy in New York  Instagram: @drpaulvin  

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

In this podcast-exclusive episode, you'll hear the original interview audio between Radio Health Journal producer Polly Hansen and best-selling author John Green. The two have a conversation about his new book, Everything is Tuberculosis, and dive into Green's personal experience traveling around the world to fight for TB awareness. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Health Accelerator Challenges on Ageless Future, Cade Archibald takes listeners deep into the science and application of the Wolverine Peptide Stack—a regenerative blend featuring BPC-157 and Thymosin Beta 4 (TB-500). Designed to mimic the rapid healing of Wolverine from X-Men, this stack accelerates recovery, muscle repair, and tissue regeneration. Cade breaks down each peptide's function, shares stacking options like CJC-1295/Ipamorelin and MOTS-c, and walks through a compelling case study of a 54-year-old man who reversed muscle loss and gained strength using the protocol. Whether you're an athlete, recovering from injury, or seeking peak vitality, this episode offers a powerful blueprint for optimizing healing and performance at any age. www.agelessfuture.com

TB was out of town so another Harlan Countian joined the show this evening. John Dunson joined Vinny and talked about living in California, coaching youth sports out there and how different it is from Kentucky. Reminisced about the days at Cumberland and living in Lynch too.Become a supporter of this podcast: https://www.spreaker.com/podcast/cats-talk-wednesday--4693915/support.

This is a Grave Talks CLASSIC EPISODE! As the memories of the living fade from one generation to the next, unfortunately, so too do the resting places for their bodies. The George Pearis Cemetery in Virginia seems to be one of those places. Once a prominent resting place for a captain of the Revolutionary War, it now sits overgrown with weeds, trees, and natural elements, slowly taking over a plot of land lined with moss-covered gravestones that time and much of the living world have forgotten. Today, it seems that there may be more activity from the dead inside the stone gates of this cemetery than anyone alive, including TB patients, war fatalities, the ghost of a little boy whose life tragically ended in a hunting rifle accident, and many others. Today, we learn about the ghosts of The George Pearis Cemetery with paranormal investigator Jake Fife. This is Part Two of our conversation. If you enjoy our interviews and conversations about "The Dead," why not listen ad-free? Become a Premium Supporter of The Grave Talks Through Apple Podcasts or Patreon (http://www.patreon.com/thegravetalks) There, you will get: Access to every episode of our show, AD-FREE! Access to every episode of our show before everyone else! Other EXCLUSIVE supporter perks and more!

This is a Grave Talks CLASSIC EPISODE! As the memories of the living fade from one generation to the next, unfortunately, so too do the resting places for their bodies. The George Pearis Cemetery in Virginia seems to be one of those places. Once a prominent resting place for a captain of the Revolutionary War, it now sits overgrown with weeds, trees, and natural elements, slowly taking over a plot of land lined with moss-covered gravestones that time and much of the living world have forgotten. Today, it seems that there may be more activity from the dead inside the stone gates of this cemetery than anyone alive, including TB patients, war fatalities, the ghost of a little boy whose life tragically ended in a hunting rifle accident, and many others. Today, we learn about the ghosts of The George Pearis Cemetery with paranormal investigator Jake Fife. If you enjoy our interviews and conversations about "The Dead," why not listen ad-free? Become a Premium Supporter of The Grave Talks Through Apple Podcasts or Patreon (http://www.patreon.com/thegravetalks) There, you will get: Access to every episode of our show, AD-FREE! Access to every episode of our show before everyone else! Other EXCLUSIVE supporter perks and more!

On The WireAdam Howe and Kevin Hasting break down all the FAAB related news from the week and shine a spotlight on who may be available to pick up in your weekly FAAB bids. Michael King to IL with scapula injury, slept awkwardly Lane Thomas to IL with right foot fasciitis Jake Mangum returns to TB from the IL and Chandler Simpson gets the boot to AAA to make room; Kyle Gibson signs with TBPIT welcomes back Endy Rodriguez at the expense of Joey Bart hitting the 7-day concussion ILDL Hall reinstated by MIL, Logan Henderson sent downCamilo Doval officially named SF closerCorey Seager returns to TEX; Alejandro Osuna called Wenceel Perez back for DET, while Matt Vierling is gone as quickly as he returned, hitting the IL with shoulder inflammationJordan Lawler got his chance…. And then sent right back down to AAA. CIN option Luis Mey AND trade Alexis Diaz to LAD for minor league pitcher Mike Villani (drafted just last year). Miguel Castro is out for the season with a right knee injury. Who's playing 1B now for CWS? (They just sent down their two other 1B's last week)Mike Trout returns to LAA lineup on Friday, optioning OF Matthew Lugo. LAA also signs Chris Taylor and sends down early-season phenom Kyren ParisMatt Mervis and Ronny Simon expected to be DFA'd by MIA, call up Heriberto Hernandez (OF)  and Jack Winkler (Infield). Xavier Edwards is playing 2B during his rehab assignment.Anthony Santander returns to IL with a left shoulder injury; Bo Bichette held from friday's gameAJ Smith Shawver had torn UCLJackson Jobe to IL with a flexor strainRockies get Thairo Estrada back from IL, call up Sam Hilliard. DFA Nick Martini, send Adael Amador to AAA. They also sign Orlando ArciaMountcastle left Friday's game with right hamstring discomfort, Mayo coming upBetts missing Friday waiting for Xray results on toe; stubbed it on Wednesday Join Our Discord & Support The Show: PL+ | PL Pro - Get 15% off Yearly with code PODCASTProud member of the Pitcher List Fantasy Baseball Podcast Network

In this episode, we're unpacking the appointment of Dr. Casey Means as the new U.S. Surgeon General and everything that's wrong with politicizing public health. Kristin and I get into functional medicine red flags, why “root cause” messaging can actually be dangerous, and the bizarre rise of raw milk influencers. (Spoiler: bovine tuberculosis is real, and no, we don't want it.) We also talk about how Mother's Day made us reflect on post-trauma rituals, parenting energy levels, and... potted plants. It's chaotic, a little gross, and kind of philosophical. You know—classic Knock Knock, Hi! Takeaways: Our new Surgeon General left residency six months before finishing—and that's just the beginning. Raw milk is trending again. So is tuberculosis. These two things are not unrelated. We invent “juice cleanses for your kidneys,” and no, please don't do that. Kristin makes the connection between surviving Will's cardiac arrest and suddenly keeping plants alive. And yes, we've reached the “bovine TB” phase of American wellness culture. — To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: https://glaucomflecken.com/glauc-to-me/ If you are interested in buying a book from one of our guests, check them all out here: https://www.amazon.com/shop/dr.glaucomflecken If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: https://anatomywarehouse.com/?aff=14 Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠ for more information.  Today's episode is brought to you by DAX Copilot from Microsoft. DAX Copilot is your AI assistant for automating clinical documentation and workflows helping you be more efficient and reduce the administrative burdens that cause us to feel overwhelmed and burnt out. To learn more about how DAX Copilot can help improve healthcare experiences for both you and your patients visit ⁠⁠⁠⁠⁠aka.ms/knockknockhi⁠⁠⁠⁠⁠. To learn more about Pearson Ravitz go to ⁠⁠⁠⁠http://www.pearsonravitz.com/knockknock⁠⁠⁠⁠. Produced by⁠⁠⁠⁠⁠ Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices

TB's Eagles beat reporter Andrew DiCecco gives his insights and observations from covering the Eagles on a daily basis. #philadelphiaeagles #flyeaglesfly #eagles #jalyxhunt #jalenhurts #willshipley #ainiassmithIn this episode, he gives his pre-OTAs forecast for the Eagles going into the offseason camps.

C&R react to missing out on the Purdy pay-day news! Is it already a storybook ending? Rich dumps on the Seahawks & the guys argue over Juan Soto.. again! They also have a new Soto headline to butt heads on! There's an in-depth look at the TB-12 Diet that Caleb Williams has been on since last year! Could you do it? Plus, 'LAST ONE STANDING' heats up & there's NBA history in the making!See omnystudio.com/listener for privacy information.

Covino & Rich have a new Juan Soto headline to butt heads on! Is Soto lacking enthusiasm in his new pin stripes? There's an in-depth look at the TB-12 Diet that Caleb Williams has been on since last year! Could you do it? Plus, 'LAST ONE STANDING' throws mental punches & there's NBA history in the making!See omnystudio.com/listener for privacy information.